Immunotherapy, a groundbreaking approach in the field of oncology, has significantly altered the treatment landscape for various malignancies. By harnessing the power of the body's immune system, it offers a promising alternative to conventional therapies. This article aims to provide a comprehensive understanding of the basic principles of immunotherapy.
Immunotherapy operates on the principle of stimulating or restoring the immune system's capacity to combat diseases. Unlike chemotherapy or radiation therapy, which directly target cancer cells, immunotherapy makes the body's defense mechanism robust enough to identify and destroy cancer cells.
There are several types of immunotherapy, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer. Each type functions differently but all aim to boost or restore immune function.
Monoclonal antibodies are designed to bind to specific targets on cancer cells, enhancing the immune system's ability to destroy them. Immune checkpoint inhibitors, on the other hand, block proteins that prevent immune responses, thereby allowing the immune cells to attack cancer more effectively.
Cancer vaccines work by triggering the immune system to attack specific diseases. In contrast, adoptive cell transfer involves modifying a patient's T-cells in a laboratory to enhance their ability to fight cancer, and then reintroducing them into the patient's body.
Immunotherapy has revolutionized cancer treatment, offering hope to many patients who had limited options previously. As our understanding of the immune system deepens, the potential for new and improved immunotherapies continues to grow. It is crucial for physicians to understand these fundamentals to effectively incorporate immunotherapy into their treatment regimens and to manage potential side effects.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation